

The Trendlines Group Ltd. Signs Collaboration Framework Agreement with Major Japanese Multinational Medical Device Company

Misgav, Israel – 11 February 2016 – The Trendlines Group Ltd. (the “**Company**” or “**The Trendlines Group**” and together with its subsidiaries and associated companies, the “**Group**”) has signed a definitive collaboration framework agreement (the “**Agreement**”) with a major multinational medical corporation (“**MMC**”) headquartered in Japan. Under the Agreement, the Company and the MMC shall mutually identify certain clinical opportunities in agreed fields as determined or to be determined in each statement of work which has been incorporated or will be incorporated to the Agreement. The Company’s Trendlines Labs unit will develop innovative medical device products for manufacture and marketing by the MMC.

[Trendlines Labs](#), the in-house innovation center of [The Trendlines Group](#), creates and develops technologies and products to meet critical unmet needs. Trendlines Labs’ multidisciplinary team of scientists, engineers, and medical professionals brings extensive project management experience to its focused, efficient approach to innovation.

Matching The Trendlines Group’s innovation and product development expertise with the Japanese partner’s depth of manufacturing experience and market reach, the Agreement will serve to expand and enhance the extensive product portfolio of this market-leading Japanese medical products company. Under the Agreement, risk is shared between the parties and the Company may receive milestone payments from the MMC for the achievement of specific milestones during the development period. In addition, the MMC will pay royalties to The Trendlines Group from the worldwide sale of products once the developed products come to market. The Agreement is not expected to have any material impact on the Group’s earnings per share and net tangible assets per share for the financial year ending 31 December 2016.

The Agreement expands upon a previously established relationship between The Trendlines Group and the MMC under which both the companies explored collaboration efforts. Both companies have several projects in development and are jointly exploring additional fields for product development.

Yosef Hazan, Chief Executive Officer of Trendlines Labs: “We are very excited to be working together with a medical device market leader of this caliber in the world’s second largest medical device market. Our growing number of global health care industry partners allows us to expand Trendlines Labs’ development capabilities and serves to help us fulfil our corporate mission of creating and developing technologies to improve the human condition.”

- End -

The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGXST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.